<DOC>
	<DOCNO>NCT02860494</DOCNO>
	<brief_summary>Tuberous sclerosis complex ( TSC ) rare genetic multisystem disorder characterize development hamartoma several organ ( e.g . brain , heart , kidney , liver , lung ) , skin 90 % case . Facial angiofibromas ( FA ) , present 80 % patient , stigmatize hallmark disease . Everolimus could candidate use topical formulation treat FA . This adaptive seamless Phase II/III study primary objective determine dose topical everolimus treatment FA evaluate efficacy safety topical everolimus versus placebo patient angiofibromas .</brief_summary>
	<brief_title>Topical Everolimus Patients With Tuberous Sclerosis Complex</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Tuberous Sclerosis</mesh_term>
	<mesh_term>Angiofibroma</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Patients age 2 year With definite possible diagnosis TSC With least 3 FA , diagnose dermatologist Patients ( parent legal guardian ) provide write informed consent prior participation study Willing able comply study requirement With negative blood pregnancy test screen visit use effective contraceptive method woman childbearing potential , 12 week treatment discontinuation Covered national health insurance Systemic treatment sirolimus , everolimus , immunosuppressive drug , previous 6 month Use topical tacrolimus sirolimus face , previous 6 month Destructive treatment ( laser therapy , surgery , cryotherapy ) facial angiofibromas previous 6 month Concomitant use topical treatment could affect facial erythema ( e.g . Brimonidine ) Known internal organ involvement require systemic mTOR inhibitor next 6 month Immunosuppression ( immunosuppressive disease immunosuppressive treatment ) Known chronic infectious disease Known hypersensitivity mTOR inhibitor Neutropenia &lt; 1000/mm3 Thrombopenia &lt; 75,000/mm3 Chronic renal insufficiency ( estimate Glomerular Filtration Rate &lt; 60 mls/min ) Chronic liver disease ( SGOT SGPT &gt; 3 time upper normal limit ) Uncontrolled dyslipidaemia Uncontrolled diabetes Brest feeding pregnant woman , woman childbearing age without effective method contraception treatment 12 week treatment discontinuation Subjects , Investigator 's opinion , unable unwilling comply protocol .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>2 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Tuberous sclerosis complex ( TSC )</keyword>
	<keyword>topical everolimus</keyword>
	<keyword>seamless design</keyword>
	<keyword>dose-escalation study</keyword>
	<keyword>m-TOR inhibitor</keyword>
</DOC>